NASDAQ: ANIX - Anixa Biosciences, Inc.

Rentabilité sur six mois: +12.78%
Secteur: Healthcare

Calendrier des promotions Anixa Biosciences, Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.

plus de détails
Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 1987-01-01
ISIN US03528H1095
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.anixa.com
Цена ао 3.13
Changement de prix par jour: -0.3891% (2.57)
Changement de prix par semaine: -4.83% (2.69)
Changement de prix par mois: -22.66% (3.31)
Changement de prix sur 3 mois: -19.75% (3.19)
Changement de prix sur six mois: +12.78% (2.27)
Changement de prix par an: -34.02% (3.88)
Evolution du prix sur 3 ans: -16.61% (3.07)
Evolution du prix sur 5 ans: -29.57% (3.635)
Evolution des prix sur 10 ans: 0% (2.56)
Evolution des prix depuis le début de l'année: -18.47% (3.14)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 470.6 1
P/BV 4.23 4
P/E 0 0
EV/EBITDA -8.95 0
Total: 2.5

Efficacité

Nom Signification Grade
ROA, % -38.44 0
ROE, % -40.31 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.016 10
Total: 10

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % -80.91 0
Rentabilité Ebitda, % 3.44 1
Rentabilité EPS, % -46.19 0
Total: 1
Plus de détails

Établissements Volume Partager, %
Vanguard Group Inc 1392906 4.37
UBS Group AG 580578 1.82
Mission Wealth Management, LLC 501168 1.57
Laird Norton Trust Company, LLC 368835 1.16
Geode Capital Management, LLC 312472 0.98
Long Focus Capital Management, LLC 165701 0.52
Blackrock Inc. 156797 0.49
State Street Corporation 108500 0.34
Bank Of New York Mellon Corporation 96654 0.3
Susquehanna International Group, LLP 73303 0.23

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares Micro-Cap ETF 0.02692 17.09 1.54048
Dimensional U.S. Core Equity 2 ETF 0.00005 30.76 1.47098



Superviseur Titre d'emploi Paiement Année de naissance
Dr. Amit Kumar Ph.D. CEO, Chairman & Co-Chair of CBAB 1.29M 1964 (61 année)
Mr. Michael J. Catelani CPA, MBA President, COO, CFO & Corporate Secretary 788.83k 1967 (58 années)
Mr. John Roop Senior Vice President of Engineering 275k 1950 (75 années)
Dr. Pamela D. Garzone Ph.D. Chief Development Officer & Chair Breast Cancer Clinical Advisory Board 1955 (70 années)

Adresse: United States, San Jose. CA, 3150 Almaden Expressway - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.anixa.com